Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iovance Biotherapeutics, Inc.

2.75
-0.0800-2.83%
Post-market: 2.75-0.0004-0.01%18:10 EDT
Volume:8.16M
Turnover:22.57M
Market Cap:918.32M
PE:-2.23
High:2.84
Open:2.80
Low:2.70
Close:2.83
Loading ...

Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
01 Mar

Iovance Shares Fall After Sales of Cancer Drug Miss Estimate

Dow Jones
·
01 Mar

Iovance Biotherapeutics (NasdaqGM:IOVA) Reports Surge in Q4 Revenue to US$74M with Improved Losses

Simply Wall St.
·
01 Mar

Truist Adjusts Price Target on Iovance Biotherapeutics to $15 From $25, Maintains Buy Rating

MT Newswires Live
·
28 Feb

Stock Track | Iovance Biotherapeutics Plunges Nearly 28% as Disappointing Earnings and Guidance Spook Investors

Stock Track
·
28 Feb

Stock Track | Iovance Biotherapeutics Plummets 27.66% on Disappointing Q4 Results and Cash Burn Outlook

Stock Track
·
28 Feb

IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty

Zacks
·
28 Feb

Wall Street Set to Open Higher Friday as Inflation Data Meets Expectations

MT Newswires Live
·
28 Feb

Iovance Biotherapeutics Is Maintained at Neutral by Piper Sandler

Dow Jones
·
28 Feb

Iovance Biotherapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

Stock Track | Iovance Biotherapeutics Plunges 17.49% in Pre-Market After Q4 Earnings Miss and Disappointing Guidance

Stock Track
·
28 Feb

Iovance Biotherapeutics Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
28 Feb

Iovance Biotherapeutics Inc (IOVA) Q4 2024 Earnings Call Highlights: Strong Revenue and ...

GuruFocus.com
·
28 Feb

U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp

Reuters
·
28 Feb

Stock Track | Iovance Biotherapeutics Plunges 16.54% as Q4 Earnings and Guidance Disappoint

Stock Track
·
28 Feb

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
28 Feb

Iovance Biotherapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Stock Track | Iovance Biotherapeutics Plunges 7.97% After Hours on Disappointing Q4 Earnings and Guidance

Stock Track
·
28 Feb

Iovance Biotherapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
28 Feb

Iovance Biotherapeutics Q4 2024 GAAP EPS $(0.26) Beats $(0.27) Estimate, Sales $73.700M Beat $72.393M Estimate

Benzinga
·
28 Feb